Latest News for: genitourinary

Edit

Propella Therapeutics Presents Non-Clinical Data on PRL-02 at 2022 ASCO Genitourinary (GU) Cancers Symposium

Nasdaq Globe Newswire 15 Feb 2022
Highlights Potential of PRL-02 as Best-in-Class, Next-Generation Androgen Biosynthesis Inhibitor for Treatment of Advanced Prostate Cancer ... .
Edit

BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium (BioXcel Therapeutics Inc)

Public Technologies 14 Feb 2022
). BioXcel Therapeutics Presents Positive Data from Phase 2 Trial of BXCL701 in Aggressive Forms of Prostate Cancer at 2022 ASCO Genitourinary Cancers Symposium. February 14, 2022 ... NEW HAVEN, Conn., Feb ... (Nasdaq ... Results will be highlighted in two poster presentations at the 2022 ASCO Genitourinary Cancers Symposium on February 17, 2022 ... Title. BXCL701.
Edit

OnQuality Pharmaceuticals to Present NOVA-II Phase 2 Trial Update and Oncologist Survey Demonstrating Oncodermatology Unmet ...

Ellensburg Daily Record 14 Feb 2022
... today announced it will be presenting two posters on Hand-Foot Skin Reaction (HFSR), including a Trial in Progress on its NOVA-II Phase 2 study and the results of an oncologist survey, at the American Society of Clinical Oncology - Genitourinary Cancers Symposium (ASCO GU).
  • 1
×